Involvement of the α(1D)-adrenergic Receptor in Methamphetamine-induced Hyperthermia and Neurotoxicity in Rats

Overview

Journal Neurotox Res

Publisher Springer

Specialty Neurology

Date 2013 Jan 4

PMID 23283760

Citations 4

Authors

Kazue Kikuchi-Utsumi

Mami Ishizaka

Nobuko Matsumura

Masahiko Watabe

Koji Aoyama

Nobuyuki Sasakawa

Toshio Nakaki

Affiliations

Soon will be listed here.

Abstract

Methamphetamine (METH) is a psychostimulant that damages nigrostriatal dopaminergic terminals, primarily by enhancing dopamine and glutamate release. α₁-adrenergic receptor (AR) subtype involved in METH-induced neurotoxicity in rats was investigated using selective α₁-AR antagonists. METH neurotoxicity was evaluated by (1) measuring body temperature; (2) determining tyrosine hydroxylase (TH) immunoreactivity levels; (3) examining levels of dopamine and its metabolites; and (4) assessing glial fibrillary acidic protein (GFAP) and microglial immunoreactivity in the striatum. METH caused a decrease in dopamine and TH levels and induced hyperthermia which is an exacerbating factor of METH neurotoxicity. Concurrently, METH increased GFAP expression and the number of activated microglia. Pretreatment with prazosin, a nonselective α₁-AR antagonist, completely abolished METH-induced decrease in both dopamine and TH and caused a partial reduction in hyperthermia. Prazosin also prevented METH-induced increase in both GFAP expression and the number of activated microglia. In vivo microdialysis analysis revealed that prazosin, however, does not alter the METH-induced dopamine release in the striatum. The neuroprotective effects of prazosin could be mimicked by a selective α(1D) antagonist, BMY 7378, but not by selective α(1A) or α(1B) antagonists. These results suggest that the α(1D)-AR is involved in METH-induced hyperthermia and neurotoxicity in rats.

Citing Articles

Pharmacological Treatments for Methamphetamine Use Disorder: Current Status and Future Targets.

Yates J Subst Abuse Rehabil. 2024; 15:125-161.

PMID: 39228432 PMC: 11370775. DOI: 10.2147/SAR.S431273.

Role of Microglia in Psychostimulant Addiction.

da Silva M, Iglesias L, Candelario-Jalil E, Khoshbouei H, Moreira F, de Oliveira A Curr Neuropharmacol. 2022; 21(2):235-259.

PMID: 36503452 PMC: 10190137. DOI: 10.2174/1570159X21666221208142151.

TBHQ-Overview of Multiple Mechanisms against Oxidative Stress for Attenuating Methamphetamine-Induced Neurotoxicity.

Zhao Y, Zhao W, Liu M, Liu L, Wang Y Oxid Med Cell Longev. 2020; 2020:8874304.

PMID: 33354283 PMC: 7735854. DOI: 10.1155/2020/8874304.

Stress-induced microglial activation occurs through β-adrenergic receptor: noradrenaline as a key neurotransmitter in microglial activation.

Sugama S, Takenouchi T, Hashimoto M, Ohata H, Takenaka Y, Kakinuma Y J Neuroinflammation. 2019; 16(1):266.

PMID: 31847911 PMC: 6916186. DOI: 10.1186/s12974-019-1632-z.

References

Sonsalla P, Riordan D, Heikkila R . Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice. J Pharmacol Exp Ther. 1991; 256(2):506-12. View

OCallaghan J, Miller D . Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther. 1994; 270(2):741-51. View

Shibata K, Foglar R, Horie K, Obika K, Sakamoto A, Ogawa S . KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol. 1995; 48(2):250-8. View

Herring N, Gudelsky G, Vorhees C, Williams M . (+)-Methamphetamine-induced monoamine reductions and impaired egocentric learning in adrenalectomized rats is independent of hyperthermia. Synapse. 2010; 64(10):773-85. PMC: 2921964. DOI: 10.1002/syn.20784. View

Fumagalli F, Gainetdinov R, Valenzano K, Caron M . Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J Neurosci. 1998; 18(13):4861-9. PMC: 6792558. View

Mark K, Soghomonian J, Yamamoto B . High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J Neurosci. 2004; 24(50):11449-56. PMC: 6730359. DOI: 10.1523/JNEUROSCI.3597-04.2004. View

Sommermeyer H, Frielingsdorf J, Knorr A . Effects of prazosin on the dopaminergic neurotransmission in rat brain. Eur J Pharmacol. 1995; 276(3):267-70. DOI: 10.1016/0014-2999(95)00062-p. View

Marshall J, ODell S, Weihmuller F . Dopamine-glutamate interactions in methamphetamine-induced neurotoxicity. J Neural Transm Gen Sect. 1993; 91(2-3):241-54. DOI: 10.1007/BF01245234. View

Hieble J, Bylund D, Clarke D, Eikenburg D, Langer S, Lefkowitz R . International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. Pharmacol Rev. 1995; 47(2):267-70. View

10.

Makisumi T, Yoshida K, Watanabe T, Tan N, Murakami N, Morimoto A . Sympatho-adrenal involvement in methamphetamine-induced hyperthermia through skeletal muscle hypermetabolism. Eur J Pharmacol. 1999; 363(2-3):107-12. DOI: 10.1016/s0014-2999(98)00758-4. View

11.

Albers D, Sonsalla P . Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther. 1995; 275(3):1104-14. View

12.

Thomas D, Dowgiert J, Geddes T, Francescutti-Verbeem D, Liu X, Kuhn D . Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci Lett. 2004; 367(3):349-54. DOI: 10.1016/j.neulet.2004.06.065. View

13.

Kita T, Wagner G, Nakashima T . Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. J Pharmacol Sci. 2003; 92(3):178-95. DOI: 10.1254/jphs.92.178. View

14.

LaVoie M, Card J, Hastings T . Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp Neurol. 2004; 187(1):47-57. DOI: 10.1016/j.expneurol.2004.01.010. View

15.

Hiraizumi-Hiraoka Y, Tanaka T, Yamamoto H, Suzuki F, Muramatsu I . Identification of alpha-1L adrenoceptor in rabbit ear artery. J Pharmacol Exp Ther. 2004; 310(3):995-1002. DOI: 10.1124/jpet.104.066985. View

16.

Hayashi R, Ohmori E, Isogaya M, Moriwaki M, Kumagai H . Design and synthesis of selective alpha1B adrenoceptor antagonists. Bioorg Med Chem Lett. 2006; 16(15):4045-7. DOI: 10.1016/j.bmcl.2006.05.002. View

17.

Battaglia G, Fornai F, Busceti C, Lembo G, Nicoletti F, de Blasi A . Alpha-1B adrenergic receptor knockout mice are protected against methamphetamine toxicity. J Neurochem. 2003; 86(2):413-21. DOI: 10.1046/j.1471-4159.2003.01867.x. View

18.

Hjorth S, Bengtsson H, Milano S, Lundberg J, Sharp T . Studies on the role of 5-HT1A autoreceptors and alpha 1-adrenoceptors in the inhibition of 5-HT release--I. BMY7378 and prazosin. Neuropharmacology. 1995; 34(6):615-20. DOI: 10.1016/0028-3908(95)00038-8. View

19.

Thomas D, Angoa Perez M, Francescutti-Verbeem D, Shah M, Kuhn D . The role of endogenous serotonin in methamphetamine-induced neurotoxicity to dopamine nerve endings of the striatum. J Neurochem. 2010; 115(3):595-605. PMC: 2974310. DOI: 10.1111/j.1471-4159.2010.06950.x. View

20.

Matsubara Y, Kanazawa T, Kojima Y, Abe Y, Kobayashi K, Kanbe H . [Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006; 126 Spec no.:237-45. DOI: 10.1248/yakushi.126.237. View